UNASSIGNED: Data were sourced from medical records at a Chinese medical facility, involving 34 patients diagnosed with ES-SCLC after failing first-line treatment. Patients were divided into two groups: one received camrelizumab (200 mg every 3 weeks) with anlotinib (12 mg daily for 14 days followed by a 7-day rest), while the other group received physician-chosen chemotherapy administered every 3 weeks. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
UNASSIGNED: The combination therapy group showed a significant improvement in PFS compared to the chemotherapy group (median PFS: 7 months vs. 3 months; hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.77; p<0.001). However, there was no statistically significant difference in OS between the groups (16.3 months vs. 17.3 months; p=0.82). The ORR was 52.9% in the combination therapy group versus 23.5% in the chemotherapy group (p=0.08), and the DCR was 82.4% compared to 58.8% (p=0.26). Grade 3 or higher adverse events were observed in 17.6% of the combination therapy group and 29.4% of the chemotherapy group.
UNASSIGNED: The findings suggest that the combination of camrelizumab and anlotinib offers a superior anti-tumor response with a manageable safety profile in a second-line setting for ES-SCLC patients. This combination regimen may be a viable option for second-line ES-SCLC treatment.
■数据来自中国医疗机构的医疗记录,涉及34例一线治疗失败后诊断为ES-SCLC的患者。患者分为两组:一组接受卡利珠单抗(每3周200mg)和安洛替尼(每天12mg,共14天,然后休息7天)。而另一组接受医生选择的化疗每3周一次.主要终点是无进展生存期(PFS),次要终点包括总生存期(OS),客观反应率(ORR),疾病控制率(DCR)。
■与化疗组相比,联合治疗组的PFS显着改善(中位PFS:7个月与3个月;风险比(HR):0.34;95%置信区间(CI):0.15-0.77;p<0.001)。然而,两组之间的OS无统计学差异(16.3个月vs.17.3个月;p=0.82)。联合治疗组的ORR为52.9%,而化疗组为23.5%(p=0.08),DCR为82.4%,为58.8%(p=0.26)。在联合治疗组的17.6%和化疗组的29.4%中观察到3级或更高的不良事件。
■研究结果表明,卡姆瑞珠单抗和安洛替尼的组合在二线环境中对ES-SCLC患者提供了优异的抗肿瘤反应和可控的安全性。这种组合方案可能是二线ES-SCLC治疗的可行选择。